{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=29&q=follicular+lymphoma",
    "query": {
      "q": "follicular lymphoma",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 1377,
    "total_pages": 138,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=30&q=follicular+lymphoma&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=28&q=follicular+lymphoma&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T01:48:44.418Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05660967",
      "title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Epcoritamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "75 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "75 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2023-03-06",
      "completion_date": "2026-06-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-18T01:48:44.418Z",
      "location_count": 1,
      "location_summary": "Waukesha, Wisconsin",
      "locations": [
        {
          "city": "Waukesha",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05660967"
    },
    {
      "nct_id": "NCT00732498",
      "title": "Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "In-Zevalin",
          "type": "DRUG"
        },
        {
          "name": "Y-Zevalin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2006-05-15",
      "completion_date": "2018-10-15",
      "has_results": true,
      "last_update_posted_date": "2019-09-04",
      "last_synced_at": "2026-10-18T01:48:44.418Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00732498"
    },
    {
      "nct_id": "NCT01678352",
      "title": "Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "High Risk WHO Grade II Glioma",
        "Recurrent/Post-Chemotherapy WHO Grade II Glioma"
      ],
      "interventions": [
        {
          "name": "Tumor Lysate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Imiquimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Frank Lieberman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2012-10",
      "completion_date": "2018-11-08",
      "has_results": false,
      "last_update_posted_date": "2020-02-24",
      "last_synced_at": "2026-10-18T01:48:44.418Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01678352"
    },
    {
      "nct_id": "NCT00361049",
      "title": "Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "graft versus host disease prophylaxis/therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fluorescence in situ hybridization",
          "type": "GENETIC"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "in vitro-treated bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2004-09",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2010-11-05",
      "last_synced_at": "2026-10-18T01:48:44.418Z",
      "location_count": 8,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00361049"
    },
    {
      "nct_id": "NCT04889716",
      "title": "CAR-T Followed by Bispecific Antibodies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Large B-cell Lymphoma",
        "DLBCL - Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "mosunetuzumab",
          "type": "DRUG"
        },
        {
          "name": "glofitamab",
          "type": "DRUG"
        },
        {
          "name": "obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2021-11-05",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-18T01:48:44.418Z",
      "location_count": 2,
      "location_summary": "Omaha, Nebraska • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04889716"
    },
    {
      "nct_id": "NCT05205252",
      "title": "A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Hematologic Malignancy",
        "Refractory Hematologic Malignancy"
      ],
      "interventions": [
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        },
        {
          "name": "Tafasitamab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab (Intravenously)",
          "type": "DRUG"
        },
        {
          "name": "Mosunetuzumab",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab (Subcutaneously)",
          "type": "DRUG"
        },
        {
          "name": "Hyaluronidase-Fihj",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone 20mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Epizyme, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-12-22",
      "completion_date": "2023-07-05",
      "has_results": false,
      "last_update_posted_date": "2023-08-15",
      "last_synced_at": "2026-10-18T01:48:44.418Z",
      "location_count": 3,
      "location_summary": "Santa Fe, California • Bolivar, Missouri • East Brunswick, New Jersey",
      "locations": [
        {
          "city": "Santa Fe",
          "state": "California"
        },
        {
          "city": "Bolivar",
          "state": "Missouri"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05205252"
    },
    {
      "nct_id": "NCT01510184",
      "title": "Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma",
        "Follicle Center Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zevalin",
          "type": "DRUG"
        },
        {
          "name": "Y-90-Zevalin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "In-111 Zevalin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2012-04-19",
      "completion_date": "2014-10-23",
      "has_results": true,
      "last_update_posted_date": "2021-12-16",
      "last_synced_at": "2026-10-18T01:48:44.418Z",
      "location_count": 28,
      "location_summary": "Casa Grande, Arizona • Berkeley, California • Duarte, California + 24 more",
      "locations": [
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01510184"
    },
    {
      "nct_id": "NCT07101328",
      "title": "A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "B-cell Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Follicular",
        "Lymphoma, B-cell Marginal Zone",
        "Waldenstrom Macroglobulinemia",
        "Lymphoma, Mantle Cell"
      ],
      "interventions": [
        {
          "name": "LY4152199 - IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2026-05-28",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-18T01:48:44.418Z",
      "location_count": 23,
      "location_summary": "Duarte, California • Aurora, Colorado • Denver, Colorado + 17 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07101328"
    },
    {
      "nct_id": "NCT00004875",
      "title": "Heparin or Enoxaparin in Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphoma",
        "Thromboembolism",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "1996-07",
      "completion_date": "1999-03",
      "has_results": false,
      "last_update_posted_date": "2011-02-21",
      "last_synced_at": "2026-10-18T01:48:44.418Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Evanston, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004875"
    },
    {
      "nct_id": "NCT01231919",
      "title": "MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Acute Leukemias of Ambiguous Lineage",
        "Acute Myeloid Leukemia/Transient Myeloproliferative Disorder",
        "Acute Undifferentiated Leukemia",
        "Aggressive NK-cell Leukemia",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Childhood Burkitt Lymphoma",
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Diffuse Large Cell Lymphoma",
        "Childhood Grade III Lymphomatoid Granulomatosis",
        "Childhood Immunoblastic Large Cell Lymphoma",
        "Childhood Nasal Type Extranodal NK/T-cell Lymphoma",
        "Chronic Eosinophilic Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Neutrophilic Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Intraocular Lymphoma",
        "Juvenile Myelomonocytic Leukemia",
        "Mast Cell Leukemia",
        "Myeloid/NK-cell Acute Leukemia",
        "Noncutaneous Extranodal Lymphoma",
        "Post-transplant Lymphoproliferative Disorder",
        "Primary Central Nervous System Hodgkin Lymphoma",
        "Primary Central Nervous System Non-Hodgkin Lymphoma",
        "Progressive Hairy Cell Leukemia, Initial Treatment",
        "Prolymphocytic Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Anaplastic Large Cell Lymphoma",
        "Recurrent Childhood Grade III Lymphomatoid Granulomatosis",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Relapsing Chronic Myelogenous Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Akt inhibitor MK2206",
          "type": "DRUG"
        },
        {
          "name": "diagnostic laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 45,
      "start_date": "2011-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-04-29",
      "last_synced_at": "2026-10-18T01:48:44.418Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231919"
    }
  ]
}